HUE041133T2 - Dalbavancin adagolási módszer bakteriális fertõzések kezelésére - Google Patents

Dalbavancin adagolási módszer bakteriális fertõzések kezelésére

Info

Publication number
HUE041133T2
HUE041133T2 HUE03789744A HUE03789744A HUE041133T2 HU E041133 T2 HUE041133 T2 HU E041133T2 HU E03789744 A HUE03789744 A HU E03789744A HU E03789744 A HUE03789744 A HU E03789744A HU E041133 T2 HUE041133 T2 HU E041133T2
Authority
HU
Hungary
Prior art keywords
dalbavancin
administering
treatment
methods
bacterial infections
Prior art date
Application number
HUE03789744A
Other languages
English (en)
Inventor
Marco Cavaleri
Timothy Henkel
Daniela Jabes
Adriano Malabarba
Giorgio Mosconi
Martin Stogniew
Richard White
Original Assignee
Vicuron Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32330046&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE041133(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vicuron Pharmaceuticals Llc filed Critical Vicuron Pharmaceuticals Llc
Publication of HUE041133T2 publication Critical patent/HUE041133T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HUE03789744A 2002-11-18 2003-11-14 Dalbavancin adagolási módszer bakteriális fertõzések kezelésére HUE041133T2 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42765402P 2002-11-18 2002-11-18
US48569403P 2003-07-08 2003-07-08
US49504803P 2003-08-13 2003-08-13
US49648303P 2003-08-19 2003-08-19

Publications (1)

Publication Number Publication Date
HUE041133T2 true HUE041133T2 (hu) 2019-05-28

Family

ID=32330046

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE03789744A HUE041133T2 (hu) 2002-11-18 2003-11-14 Dalbavancin adagolási módszer bakteriális fertõzések kezelésére

Country Status (15)

Country Link
US (12) US20050090433A1 (hu)
EP (1) EP1565201B1 (hu)
JP (3) JP5519090B2 (hu)
KR (2) KR20120056310A (hu)
AU (3) AU2003298662A1 (hu)
CA (1) CA2506236C (hu)
DK (1) DK1565201T3 (hu)
ES (1) ES2712656T3 (hu)
HK (2) HK1083684A1 (hu)
HU (1) HUE041133T2 (hu)
IL (3) IL168327A (hu)
MX (1) MXPA05005338A (hu)
NO (1) NO20052362L (hu)
PT (1) PT1565201T (hu)
WO (3) WO2004046196A2 (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05005338A (es) * 2002-11-18 2005-12-14 Vicuron Pharm Inc Metodos para administrar dalbavancin para el tratamiento de infecciones bacterianas.
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20090062182A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched dalbavancin
US8389583B2 (en) * 2008-05-23 2013-03-05 Zurex Pharma, Inc. Antimicrobial compositions and methods of use
US20110132607A1 (en) * 2009-12-07 2011-06-09 Schlumberger Technology Corporation Apparatus and Technique to Communicate With a Tubing-Conveyed Perforating Gun
JP6540705B2 (ja) 2013-12-19 2019-07-10 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ 生物学的液体処理システムのための遠隔操作弁
JP6712991B2 (ja) 2014-07-17 2020-06-24 ザ メディシンズ カンパニー 高純度のオリタバンシン及びその製造方法
NZ731955A (en) 2014-11-06 2023-07-28 Xellia Pharmaceuticals Aps Glycopeptide compositions
KR20200040286A (ko) * 2015-03-02 2020-04-17 코로나리콘셉츠 엘엘씨 Peg 대사산물 및 peg 분해 생성물 검정을 위한 화합물 및 방법
US10071141B2 (en) 2015-05-08 2018-09-11 Spectral Platforms, Inc. Albumin-based non-covalent complexes and methods of use thereof
WO2017179003A1 (en) 2016-04-15 2017-10-19 Lupin Limited Topical compositions for ophthalmic and otic use
EP3602065A4 (en) 2017-03-20 2020-12-23 Spectral Platforms, Inc. SPECTROSCOPIC METHODS OF DETECTION AND CHARACTERIZATION OF MICROORGANISMS
JP2020527551A (ja) * 2017-07-10 2020-09-10 コントラフェクト コーポレイション 血液成分による溶菌タンパク質の抗菌活性の強化、並びにその方法及び使用
CN110183519B (zh) * 2019-05-06 2023-04-11 大邦(湖南)生物制药有限公司 一种达巴万星关键中间体a40926的分离纯化方法
CN112480214B (zh) * 2020-12-14 2023-03-28 成都雅途生物技术有限公司 一种达巴万星关键中间体a40926的制备方法
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
MX2023008148A (es) 2021-01-11 2023-07-24 Xellia Pharmaceuticals Aps Proceso de sintesis.
CN115215926A (zh) * 2022-08-12 2022-10-21 丽珠集团福州福兴医药有限公司 达巴万星母核及其纯化方法、达巴万星及其合成方法
WO2024079224A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition
WO2024079223A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US573679A (en) * 1896-12-22 Apparatus for mowing hay
US541616A (en) * 1895-06-25 Elevator attachment
GB1496386A (en) * 1975-03-05 1977-12-30 Lepetit Spa Antibiotics
US4195079A (en) * 1979-01-31 1980-03-25 Pfizer Inc. New polycyclic ether antibiotic
CA1183789A (en) 1981-08-04 1985-03-12 Kiyoshi Isono Antibiotic 76-11, process for the production thereof, anticoccidiosis agent and domestic animals growth accelerator comprising the same as an effective ingredient
US4578271A (en) 1982-05-24 1986-03-25 Fujisawa Pharmaceutical Co., Ltd. Biologically active WS 6049 substances, a process for the production thereof and their pharmaceutical compositions
FI73697C (fi) * 1982-06-08 1987-11-09 Lepetit Spa Foerfarande foer framstaellning av individuella faktorer 1, 2, 3, 4 och 5 av teikomysin a2.
FR2548021B1 (fr) 1983-06-29 1986-02-28 Dick P R Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
GB8415092D0 (en) * 1984-06-13 1984-07-18 Lepetit Spa Ester derivatives
GB8425685D0 (en) 1984-10-11 1984-11-14 Lepetit Spa Antibiotic a 40926 complex
GB8428619D0 (en) * 1984-11-13 1984-12-19 Lepetit Spa Derivatives of antibiotic l 17046
US4914187A (en) * 1984-11-13 1990-04-03 Gruppo Lepetit S.P.A Ester derivatives of antibiotic L 17046
GB8512795D0 (en) 1985-05-21 1985-06-26 Lepetit Spa Increasing ratio of components of teicoplanin a2 complex
GB8531846D0 (en) 1985-12-30 1986-02-05 Lepetit Spa Antibiotic a 40926 mannosyl aglycon
GB8608809D0 (en) * 1986-04-11 1986-05-14 Lepetit Spa Antibiotic
GB8621912D0 (en) * 1986-09-11 1986-10-15 Lepetit Spa Increasing ratio of components of anti-biotic complex
GB8621911D0 (en) * 1986-09-11 1986-10-15 Lepetit Spa Increasing ratio of components of anti-biotic complex
GR871488B (en) 1986-10-10 1987-11-12 Lepetit Spa New antibiotics
GB8715735D0 (en) * 1987-07-03 1987-08-12 Lepetit Spa De-mannosyl teicoplanin derivatives
US4882313A (en) 1987-07-31 1989-11-21 Smithkline Beckman Corporation Carboxamide derivatives of glycopeptides
GB8726859D0 (en) 1987-11-17 1987-12-23 Lepetit Spa 22-dechlorotei-coplanins
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
FR2628269B1 (fr) * 1988-03-04 1990-07-27 Sgs Thomson Microelectronics Dispositif de demarrage progressif d'une alimentation a decoupage
ES2083374T3 (es) 1988-12-27 1996-04-16 Lepetit Spa Derivados amidicos en posicion c63 de 34-des(acetilglucosaminil)-34-desoxi-teicoplaninas.
IE64155B1 (en) 1989-03-29 1995-07-12 Lepetit Spa New substituted alkylamide derivatives of teicoplanin
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
US5030619A (en) * 1990-04-16 1991-07-09 Miles Inc. Synergistic fungicidal composition
US5606036A (en) * 1991-03-27 1997-02-25 Gruppo Lepetit Spa Antibiotic A 40926 ester derivatives
JP2783722B2 (ja) * 1991-07-12 1998-08-06 麒麟麦酒株式会社 スピカマイシン誘導体およびそれを含む抗腫瘍剤
US5750509A (en) * 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
RU2125058C1 (ru) 1991-07-29 1999-01-20 Группо Лепетит С.П.А. Производное антибиотика а 40926, способы его получения, фармацевтическая композиция
US6384013B1 (en) * 1992-03-19 2002-05-07 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US5882900A (en) * 1992-09-10 1999-03-16 Gruppo Lepetit S.P.A. Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium
CA2112776C (en) * 1993-01-21 2002-11-12 Masakazu Tsuchiya Process for inhibiting activity of endotoxin
WO1994025588A2 (en) * 1993-04-30 1994-11-10 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β)
DK0801655T3 (da) * 1995-02-07 1999-02-08 Biosearch Italia Spa Basiske prolinamidderivater af GE 2270 og GE 2270-lignende antibiotika
JP3518606B2 (ja) * 1995-02-07 2004-04-12 バイオサーチ・イタリア・ソチエタ・ペル・アチオニ Ｇｅ２２７０及びｇｅ２２７０−様抗生物質の塩基性オキサゾリン−アミド誘導体
SI9500039B (sl) * 1995-02-07 2002-02-28 Lek, Nov kombiniran postopek čiščenja Vankomicin hidroklorida
US5789308A (en) * 1995-06-06 1998-08-04 Advanced Micro Devices, Inc. Manufacturing method for wafer slice starting material to optimize extrinsic gettering during semiconductor fabrication
EP0750913A3 (en) * 1995-06-30 1997-11-05 Takeda Chemical Industries, Ltd. Disaccharide containing freeze-dried preparation for pharmaceutical use
JP4051421B2 (ja) * 1995-07-05 2008-02-27 サノフイ−アベンテイス・エツセ・ピー・アー 等電点電気泳動によるダルバヘプチド抗生物質の精製
DE19600590A1 (de) * 1996-01-10 1997-07-24 Tzn Forschung & Entwicklung Schutzvorrichtung für optische Systeme zur Vermeidung von Schäden bei Bestrahlung dieser Systeme mit Laserlicht
EP0880541B1 (en) * 1996-02-14 2003-01-15 Biosearch Italia S.p.A. Derivatives of antibiotic ge2270 factors
AU2441697A (en) 1996-04-12 1997-11-07 Eli Lilly And Company Covalently-linked glycopeptide dimers
CA2250578C (en) * 1996-04-23 2003-06-24 Versicor Inc. Improved chemical process for preparing amide derivatives of antibiotic a 40926
US5935238A (en) * 1997-06-19 1999-08-10 Sun Microsystems, Inc. Selection from multiple fetch addresses generated concurrently including predicted and actual target by control-flow instructions in current and previous instruction bundles
JP4204655B2 (ja) * 1997-08-08 2009-01-07 株式会社ルネサステクノロジ パルス出力機能付マイクロコンピュータ
EP0931834A3 (en) 1997-12-23 2002-06-26 Eli Lilly And Company Echinocandin binding domain of 1,3-Beta-glucan synthase
US6541616B1 (en) * 1998-10-01 2003-04-01 Antex Biologics Inc. Moraxella catarrhalis protein, gene sequence and uses thereof
US6417180B1 (en) 1998-10-07 2002-07-09 University Of Massachusetts Zinc finger-reactive antimicrobial compounds
WO2000039156A1 (en) * 1998-12-23 2000-07-06 Advanced Medicine, Inc. Glycopeptide derivatives and pharmaceutical compositions containing the same
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
AU2001259298A1 (en) 2000-05-02 2001-11-12 Advanced Medicine, Inc. Polyacid glycopeptide derivatives
WO2003070756A2 (de) 2002-02-18 2003-08-28 Combinature Biopharm Ag Neue glycopeptid-antibiotika und verfahren zu deren synthetisierung
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
MXPA05005338A (es) 2002-11-18 2005-12-14 Vicuron Pharm Inc Metodos para administrar dalbavancin para el tratamiento de infecciones bacterianas.

Also Published As

Publication number Publication date
US20040142883A1 (en) 2004-07-22
CA2506236C (en) 2018-07-17
JP2011157381A (ja) 2011-08-18
KR20120056310A (ko) 2012-06-01
JP2013155188A (ja) 2013-08-15
US20050004011A1 (en) 2005-01-06
IL230875A0 (en) 2014-03-31
JP2006514092A (ja) 2006-04-27
NO20052362D0 (no) 2005-05-12
US7115564B2 (en) 2006-10-03
US20040197415A1 (en) 2004-10-07
IL239913B (en) 2019-01-31
US20050130914A1 (en) 2005-06-16
IL239913A0 (en) 2015-08-31
US20050032721A1 (en) 2005-02-10
IL168327A (en) 2014-02-27
AU2003294262A1 (en) 2004-06-15
EP1565201A1 (en) 2005-08-24
WO2004045637A1 (en) 2004-06-03
US20090305953A1 (en) 2009-12-10
AU2003294262B2 (en) 2007-08-23
ES2712656T3 (es) 2019-05-14
MXPA05005338A (es) 2005-12-14
NO20052362L (no) 2005-08-17
US20090298748A1 (en) 2009-12-03
US20040224908A1 (en) 2004-11-11
US20050130909A1 (en) 2005-06-16
WO2004046196A3 (en) 2004-08-19
PT1565201T (pt) 2019-02-05
HK1083684A1 (en) 2006-07-07
EP1565201B1 (en) 2018-10-31
WO2004045636A1 (en) 2004-06-03
CA2506236A1 (en) 2004-06-03
DK1565201T3 (en) 2019-02-25
US20050090433A1 (en) 2005-04-28
US20040198715A1 (en) 2004-10-07
US20040220122A1 (en) 2004-11-04
KR101173310B1 (ko) 2012-08-10
HK1114014A1 (en) 2008-10-24
AU2003299561A1 (en) 2004-06-15
KR20050094396A (ko) 2005-09-27
WO2004046196A2 (en) 2004-06-03
US6900175B2 (en) 2005-05-31
AU2003298662A1 (en) 2004-06-15
JP5519090B2 (ja) 2014-06-11

Similar Documents

Publication Publication Date Title
HK1083684A1 (en) Methods of administering dalbavancin for treatmentof bacterial infections
AU2003901008A0 (en) Composition for the treatment and prevention of bacterial infections
GB0125222D0 (en) Composition for the treatment of microbial infections
EP1531828A4 (en) METHODS OF TREATING BACTERIAL INFECTIONS AND ASSOCIATED DISEASES
ZA200507070B (en) Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
HK1103639A1 (en) Dalbavancin compositions for treatment of bacterial infections
EP1594444A3 (en) Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
IL180459A0 (en) Treatment of bacterial infections
PL371524A1 (en) Combination therapy for the treatment of bacterial infections
GB2401788B (en) Treatment of surfaces populated by bacteria
AU2003291886A1 (en) Thiophenederivatives for the treatment of flavivirus infections
PL374524A1 (en) Composition based on triethyl citrate for the treatment of bacterial infections of the skin
AU2003260818A1 (en) Treatment of immune system dysfunction
AU2003220338A8 (en) Photosensitizers for photodynamic therapy of microbial infections
AU2003290506A8 (en) Methods and devices for treating severe peripheral bacterial infections
GB0217493D0 (en) Novel methods of treatment
GB0221712D0 (en) Methods of treatment
AU2003304316A8 (en) Compounds and methods for the treatment and prevention of bacterial infection
HK1069739A1 (en) Compositions and methods for treatment of microbial infections
AU2003209241A1 (en) Antimicrobial thiadiazinone derivatives useful in treatment of bacterial infections
AU2003267962A8 (en) Antibacterial compounds and methods for treating gram positive bacterial infections
AUPR967401A0 (en) Treatment of bacterial infections
AU2003214918A1 (en) Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
AUPS219902A0 (en) Methods of treatment
AU2003904161A0 (en) Methods of treatment